CACO-2™ by NaviCyte Scientific

(Only available in English)

[vc_tabs][vc_tab title="Home" tab_id="1421322440-1-001"][vc_column_text]

Home

01
01

The NaviCyte Advantage
NaviCyte Scientific, a division of LION bioscience Inc. which is a wholly owned subsidiary of SYGNIS, AG, is the exclusive commercial licensor of the Caco-2™ cell line and its subclone, C2BBe1. The Caco-2 cell line originated in the laboratory of the Memorial Sloan-Kettering Cancer Center (MSKCC) and the cell line was deposited with the American Type Culture Collection (ATCC).

NaviCyte Scientific holds the exclusive commercial distribution rights to the Caco-2™ cell line deposited by the Memorial Sloan-Kettering Cancer Center (MSKCC) with the American Type Culture Collection (ATCC) under ATCC catalog entry HTB-37. NaviCyte also is the exclusive licensor of the Caco-2 subclone C2BBe1 deposited with ATCC in their catalogue as CRL-2102.

Note: All uses of Caco-2™ cells, other than for research use by a non-profit or academic entity, require a license and use authorization from NaviCyte Scientific under its exclusive arrangement with MSKCC — including cells obtained from ATCC or other institutions. Caco-2™ cells may not be distributed or used for any commercial uses without the prior written authorization of NaviCyte Scientific. Please navigate over left menu entries for more information.

Contact Information:
Elizabeth R Aden, PhD
NaviCyte Scientific
3030 Buena Vista Way
Berkeley, CA 94708
Phone: +1 973-868-6100
Fax: +1 510-548-7676
email: contact@navicyte-scientific.com

NaviCyte is a trademark of LION bioscience Inc. (a company of SYGNIS Group). CACO-2 is a trademark of the Memorial Sloan-Kettering Cancer Center.


[/vc_column_text][/vc_tab][vc_tab title="News" tab_id="1421322440-2-002"][vc_column_text]

Recent News about NaviCyte Scientific

01
01
For more information about any NaviCyte Scientific announcements, please contact us at contact@navicyte-scientific.com

  • NaviCyte Scientific Grants Cubist Pharmaceuticals Caco-2 Cell Line License. (January 2009)
    Navicyte Scientific, a division of LION bioscience Inc., announced that Cubist Pharmaceuticals, Inc. has obtained a non-exclusive, commercial use license for the Caco-2™ cell line. Financial details of the transaction were not disclosed. Navicyte Scientific holds an exclusive commercial use license from the Memorial Sloan Kettering Institute for Cancer Research.
  • Apredica LLC, Obtains Caco-2 Commercial Use License From NaviCyte Scientific. (December 2008)
    Apredica LLC, has obtained a non-exclusive license for commercial use of the Caco-2™ cell line. Financial details of the transaction were not disclosed.
  • NaviCyte Scientific Grants Genzyme Corporation Caco-2 License. (August 2008)
    Navicyte Scientific, a division of LION bioscience Inc., has granted Genzyme Corporation a world-wide, non-exclusive, commercial use license for the Caco-2™ cell line. Financial details of the transaction were not disclosed. Navicyte Scientific holds an exclusive commercial use license from the Memorial Sloan Kettering Institute for Cancer Research.
  • Wolfe Laboratories Inc.,Obtains Caco-2 Commercial Use License From NaviCyte Scientific. (June 2008)
    Wolfe Laboratories Inc., has obtained a non-exclusive license for commercial use of the Caco-2™ cell line. Financial details of the transaction were not disclosed.
  • Theravance, Inc. Obtains Caco-2 License. (December 2007)
    Theravance Inc. has obtained a non-exclusive commercial-use license for the Caco-2™ cell line. Financial details of the transaction were not disclosed. Navicyte Scientific holds an exclusive commercial use license from the Memorial Sloan Kettering Institute for Cancer Research.
  • NaviCyte Scientific Grants Merck & Co., Inc. Worldwide Caco-2 License. (November 2007)
    Navicyte Scientific, a division of LION bioscience Inc., announced that Merck & Co., Inc. has obtained a world-wide, non-exclusive commercial use license for the Caco-2™ cell line. Financial details of the transaction were not disclosed. Navicyte Scientific holds an exclusive commercial use license from the Memorial Sloan Kettering Institute for Cancer Research.
  • NaviCyte Scientific Grants Bristol-Myers Squibb Company a Worldwide Caco-2 License. (October 2007)
    Navicyte Scientific, a division of LION bioscience Inc., announced that Bristol-Myers Squibb Company has obtained a world-wide, non-exclusive commercial use license for the Caco-2™ cell line. Financial details of the transaction were not disclosed. Navicyte Scientific holds an exclusive commercial use license from the Memorial Sloan Kettering Institute for Cancer Research.
  • Zealand Pharma Obtains Caco-2 License From NaviCyte Scientific. (October 2007)
    Zealand Pharma A/S has obtained a non-exclusive license for commercial use of the Caco-2™ cell line. Financial details of the transaction were not disclosed.
  • Navicyte Scientific Grants Nastech Pharmaceutical Caco-2 License. (September 2007)
    Navicyte Scientific announced that Nastech Pharmaceutical Company Inc. has obtained a non-exclusive license to use the Caco-2™ cell line. Financial details of the transaction were not disclosed. NaviCyte Scientific holds an exclusive commercial use license from the Memorial Sloan Kettering Institute for Cancer Research.
  • Microbia Obtains Caco-2 Commercial Use License From NaviCyte Scientific. (August 2007)
    Microbia Inc. has obtained a non-exclusive license for commercial use of the Caco-2™ cell line. Financial details of the transaction were not disclosed.
  • NaviCyte Scientific Grants Astellas Worldwide Caco-2 License. (August 2007)
    Navicyte Scientific, a division of LION bioscience Inc., announced that Astellas Pharma Inc. has obtained a world-wide, non-exclusive commercial use license for the Caco-2™ cell line. Financial details of the transaction were not disclosed. Navicyte Scientific holds an exclusive commercial use license from the Memorial Sloan Kettering Institute for Cancer Research.
  • NaviCyte Scientific Grants Labopharm Inc. Caco-2 License. (August 2007)
    Navicyte Scientific announced that Labopharm Inc. has obtained a non-exclusive license to use the Caco-2™ cell line. Financial details of the transaction were not disclosed. NaviCyte Scientific holds an exclusive commercial use license from the Memorial Sloan Kettering Institute for Cancer Research.
  • MannKind Corporation Obtains Caco-2 Commercial Use License From NaviCyte Scientific. (July 2007)
    MannKind Corporation has obtained a non-exclusive license for commercial use of the Caco-2™ cell line. Financial details of the transaction were not disclosed.
  • Navicyte Scientific Grants PainCeptor Pharma Corporation Caco-2 License. (June 2007)
    Navicyte Scientific, a division of LION bioscience Inc., announced that PainCeptor Pharma Corporation has obtained a non-exclusive commercial use license for the Caco-2™ cell line. Financial details of the transaction were not disclosed. Navicyte Scientific holds an exclusive commercial use license from the Memorial Sloan Kettering Institute for Cancer Research.
  • Trinity Biosystems Obtains Caco-2 Commercial Use License From NaviCyte Scientific. (May 2007)
    Trinity Biosystems has obtained a non-exclusive license for commercial use of the Caco-2™ cell line. Financial details of the transaction were not disclosed.
  • Navicyte Scientific and the American Type Culture Collection Enter into a Collaboration Agreement for Licensing and Distribution of the Caco-2 Cell Line. (March 2007)
    Navicyte Scientific (“Navicyte”) and the American Type Culture Collection (“ATCC”) announced that they have entered into a collaboration agreement for the coordination of the licensing and distribution of the Caco-2™ cell line to commercial entities. Under the collaboration, commercial entities shall now be able to obtain a license for use of the Caco-2™ cell line from Navicyte just prior to obtaining Caco-2™ materials from ATCC. Caco-2™ cells were developed by the Sloan Kettering Institute for Cancer Research and are on deposit with ATCC. ATCC is authorized to distribute these cells into the scientific community for research use and Navicyte currently holds an exclusive commercial license from the Sloan Kettering Institute for Cancer Research for commercial use of the Caco-2™ cell line.
  • Navicyte Scientific Grants AstraZeneca Worldwide Caco-2 License. (February 2007)
    Navicyte Scientific, a division of LION bioscience Inc., announced that AstraZeneca has obtained a world-wide, non-exclusive commercial use license for the Caco-2™ cell line. Financial details of the transaction were not disclosed. Navicyte Scientific holds an exclusive commercial use license from the Memorial Sloan Kettering Institute for Cancer Research.
  • Navicyte Scientific Grants Diagnostic Hybrids Inc., an Evaluation License for the Caco-2 Cell Line. (February 2007)
    Diagnostic Hybrids has obtained a non-exclusive evaluation license for commercial use of the Caco-2™. Financial details of the transaction were not disclosed.
  • Navicyte Scientific Grants Amaxa GmbH a Commercial Use License for the Caco-2 Cell Line. (October 2006)
    NaviCyte Scientific, a division of LION bioscience Inc., announced that it has granted a non-exclusive commercial use license for the Caco-2™ cell line to Amaxa GmbH. Financial details of the transaction were not disclosed.
  • NaviCyte Scientific Grants Non-Exclusive, Worldwide Caco-2 Commercial Use License to In Vitro Technologies. (May 2006)
    LION bioscience Inc., including its NaviCyte Scientific business division, (“NaviCyte”) and In Vitro Technologies Inc. (“IVT”) announced that they have reached agreement with respect to IVT’s use of Caco-2™ cells acquired by IVT from the American Type Culture Collection (ATCC) in 1997. Caco-2™ cells were developed by the Memorial Sloan-Kettering Institute for Cancer Research and deposited with ATCC subject to commercial restrictions. NaviCyte obtained an exclusive commercial license from the Memorial Sloan-Kettering Institute for commercial use of the cell line 1997. Under the NaviCyte-IVT agreement, IVT holds a worldwide non-exclusive commercial sublicense from NaviCyte (doing business as NaviCyte Scientific) to use and distribute, as well as the use of Caco-2™ cells in IVT’s products and services, subject to end-user restrictions. As part of the agreement, both NaviCyte and IVT also have agreed to withdraw, and to refrain from pursuing all pending claims and counterclaims against each other relating to Caco-2™. Additional details of the agreement were not disclosed.
  • NaviCyte Scientific Successfully Manages Assignment of iDEA Technology and Related Intellectual Property. (May 2006)
    Navicyte Scientific announced that it successfully managed the assignment of the iDEA pkEXPRESS predictive software technology and related assets to a California-based company. iDEA pkEXPRESS is a comprehensive predictive ADME (absorption, distribution, metabolism and elimination) solution for lead optimization. Inappropriate pharmacokinetic properties have historically caused the failure of compounds in the later stages of development. The software serves as an early stage development tool to help identify chemical compounds that have appropriate ADME properties for later stage development. In this way, iDEA pkEXPRESS enables medicinal chemists and pharmacokinetic researchers involved in drug discovery to select compounds with the best ADME characteristics in order to accelerate lead optimization. Details of the transaction were not disclosed.
  • U.S. Pharmaceutical Company Obtains Caco-2 Commercial Use License From NaviCyte Scientific. (January 2006)
    A domestic pharmaceutical company has entered into a world-wide, non-exclusive, commercial use license for the Caco-2™ cell line with NaviCyte Scientific. NaviCyte granted the license under NaviCyte’s Caco-2 Up-To-Date program. Terms and conditions of the transaction were not disclosed.
  • NaviCyte Scientific Successfully Brokers Exclusive Multi-Year License of Melanocortin Receptor Technology and Intellectual Property. (July 2005)
    NaviCyte announced that it has successfully licensed assets resulting from the extensive research and drug discovery program of former Trega Biosciences Inc. involving melanocortin receptors to a San Diego based biotechnology business under an exclusive multi-year worldwide license. Melanocortin receptors regulate a diverse array of functions in the human body, including sexual arousal, feeding behavior and energy maintenance, inflammation and skin pigmentation. These receptors are considered potential building blocks for the next generation of sexual dysfunction drugs. Trega had used its combinatorial chemistry technologies to discover a family of proprietary compounds that appear to influence the production and activity of certain cytokines through interaction with melanocortin receptors. Trega’s research encompassed the development of a number of different compounds active against certain melanocortin receptors, including for the treatment of sexual dysfunction in humans. Trega also pursued a number of key patents giving Trega broad protections of the results from its melanocortin research program. NaviCyte Scientific was appointed to facilitate the licensing of these assets. Under the terms of the license, the licensee will make minimum annual license fee payments and pay certain royalties.

  • BD Biosciences Discovery Labware Receives Caco-2 Commercial Use License from NaviCyte Scientific under Caco-2 Up-To-Date Initiative. (June 2005)
    NaviCyte Scientific, a division of LION bioscience Inc., announced that BD Biosciences Discovery Labware, a wholly owned sub of BD Biosciences, a business segment of BD (Becton, Dickinson and Company), one of the largest businesses supporting the life sciences today, has obtained a non-exclusive commercial use license for the Caco-2™ cell line from NaviCyte Scientific under NaviCyte’s Caco-2 Up-To-Date Intiative. Financial details of the transaction were not disclosed.
  • Novartis Receives Worldwide Caco-2 Commercial Use License from NaviCyte Scientific under Caco-2 Up-To-Date Initiative. (June 2005)
    NaviCyte Scientific, a division of LION bioscience Inc., announced that Novartis, one of the world’s leading pharmaceutical companies, has entered into worldwide non-exclusive commercial use license for the Caco-2™ cell line from NaviCyte Scientific under NaviCyte’s Caco-2 Up-To-Date Intiative. Financial details of the transaction were not disclosed.
  • NaviCyte Scientific Receives Final Royalty Payment on Tea-Bag Technology from IRORI, a Discovery Partners International Company. (May 2005)
    NaviCyte Scientific, a division of LION bioscience Inc., announced that it has received royalty payments from IRORI, a Discovery Partners International (NASDAQ: DPII) company, with respect to the Tea-Bag Technology of former Trega Bioscienes. In May 1998, Trega had granted IRORI a non-exclusive, worldwide license to its Tea-Bag technology for use in IRORI’s Kan(TM)-style family of microreactors. Under the terms of the agreement, IRORI had agreed to pay an upfront licensing fee and a royalty on all Kan(TM)-family product sales. Earlier this year, NaviCyte had facilitated the payment of previously outstanding royalties from IRORI under the license agreement.
  • Biogen Idec Obtains Caco-2 Commercial Use License from NaviCyte Scientific under Caco-2 Up-To-Date Initiative. (March 2005)
    NaviCyte Scientific, a division of LION bioscience Inc., announced that Biogen Idec, one of the world’s leading biotechnology companies, has entered into a non-exclusive commercial use license for the Caco-2™ cell line with NaviCyte Scientific under NaviCyte’s Caco-2 Up-To-Date Intiative. Financial details of the transaction were not disclosed.
  • NaviCyte Scientific Facilities Payment of Royalties on Tea-Bag Technology from IRORI, a Discovery Partners International Company. (February 2005)
    NaviCyte Scientific, a division of LION bioscience Inc., announced that it had facilitated the payment of outstanding royalties from IRORI, a Discovery Partners International (NASDAQ: DPII) company, with respect to the Tea-Bag Technology of former Trega Bioscienes. In May 1998, Trega had granted IRORI a non-exclusive, worldwide license to its Tea-Bag technology for use in IRORI’s Kan(TM)-style family of microreactors. Under the terms of the agreement, IRORI had agreed to pay an upfront licensing fee and a royalty on all Kan(TM)-family product sales. Trega had acquired the Tea-Bag Technology under an exclusive license agreement with The Scripps Research Institute. NaviCyte Scientific expects additional payments to be paid by IRORI in the future.
  • NaviCyte Grants Caco-2 Commercial Use License to Millipore and Two Other U.S. Life Sciences Companies. (September 2004)
    NaviCyte Scientific, a division of LION bioscience Inc., announced that it has entered into a non-exclusive commercial use license for the Caco-2™ cell line with Millipore Corporation. The license was entered into under NaviCyte’s Caco-2 Up-To-Date program. Financial details of the transaction were not disclosed. In addition, NaviCyte has entered into non-exclusive commercial use licenses with two other life sciences companies under under NaviCyte’s Caco-2 Up-To-Date program having a combinged market capitalization of more than US$1.75 billion. Details of these transactions have not been published.
  • Proctor & Gamble Pharmaceuticals Obtains Commercial Use License for Caco-2 from NaviCyte. (May 2004)
    NaviCyte Scientific, a division of LION bioscience Inc., announced that it has granted a non-exclusive commercial use license for the Caco-2(TM) cell line to Proctor & Gamble Pharmaceuticals. The license was entered into under NaviCyte’s Caco-2 Up-To-Date program. Financial details of the transaction were not disclosed.
  • Major Multinational Pharmaceuticals Company Licenses Caco-2 from NaviCyte Scientific. (May 2004)
    A large multinational pharmaceutical company has entered into a global non-exclusive commercial use license for the Caco-2™ cell line with NaviCyte Scientific. NaviCyte granted the license under NaviCyte’s Caco-2 Up-To-Date program. Details of the transaction have not been published.
  • Millennium Pharmaceuticals Acquires Perpetual Commercial Use License for Caco-2 from NaviCyte. (March 2004)
    Millennium Pharmaceuticals has entered into a perpetual non-exclusive commercial use license for the Caco-2™ cell line with NaviCyte Inc. under NaviCyte’s Caco-2 Up-To-Date program. Millennium had previously licensed Caco-2 for commercial use from NaviCyte under a term license that Millennium had renewed in September 2003. NaviCyte has now extended the term of the license for a perpetual period in consideration for payment by Millennium of a perpetual use license fee in accordance with NaviCyte’s Caco-2 Up-To-Date program. Financial details of the transaction were not disclosed. The Caco-2 cell line originated in the laboratories of the Memorial Sloan-Kettering Cancer Center and have been deposited with the ATCC for non-commercial research uses only. NaviCyte is the exclusive commercial distributor and licensor of the Caco-2 cell line under an agreement with Memorial Sloan-Kettering.
  • Abbott Laboratories Obtains Commercial Use License for Caco-2 from NaviCyte. (December 2003)
    NaviCyte Inc., a subsidiary of LION bioscience Inc., is pleased to announce that Abbott Laboratories has obtained a non-exclusive commercial use license for the Caco-2™ cell line from NaviCyte Scientific under NaviCyte’s Caco-2 Up-To-Date program. Financial details of the transaction were not disclosed. The Caco-2 cell line originated in the laboratories of the Memorial Sloan-Kettering Cancer Center and have been deposited with the ATCC for non-commercial research uses only. NaviCyte is the exclusive commercial distributor and licensor of the Caco-2 cell line under an agreement with Memorial Sloan-Kettering.
  • Millennium Pharmaceuticals Renews Caco-2 License with NaviCyte. (September 2003)
    NaviCyte, Inc., a subsidiary of LION bioscience Inc., is pleased to announce that Millennium Pharmaceuticals has renewed its non-exclusive commercial use license for the Caco-2™ cell line with NaviCyte. Financial details of the transaction were not disclosed. Millennium had initially entered into a two-year commercial use license with NaviCyte which recently came up for renewal. The Caco-2 cell line originated in the laboratories of the Memorial Sloan-Kettering Cancer Center and have been deposited with the ATCC for non-commercial research uses only. NaviCyte is the exclusive commercial distributor and licensor of the Caco-2 cell line under an agreement with Memorial Sloan-Kettering.

 

NaviCyte is a trademark of LION bioscience Inc. (a company of SYGNIS Group). CACO-2 is a trademark of the Memorial Sloan-Kettering Cancer Center.


[/vc_column_text][/vc_tab][vc_tab title="Our Services" tab_id="1421322440-2-003"][vc_column_text]

Our Services

01
01
NaviCyte Scientific provides licensing for the commercial use of the Caco-2™ cell line for both internal purposes as well as other applications.

NaviCyte is a trademark of LION bioscience Inc. (a company of SYGNIS Group). CACO-2 is a trademark of the Memorial Sloan-Kettering Cancer Center.


[/vc_column_text][/vc_tab][vc_tab title="CACO-2™" tab_id="1421322440-2-004"][vc_column_text]

CACO-2™

01
01
NaviCyte Scientific holds the exclusive commercial distribution rights to the Caco-2™ cell line as deposited by the Memorial Sloan-Kettering Cancer Center (SK) with the American Type Culture Collection (ATCC) under ATCC catalog entry HTB-37.

Note: All uses of Caco-2™ cells, other than for research by a non-profit or academic entity, require a license and use authorization from NaviCyte Scientific under its exclusive arrangement with Memorial Sloan-Kettering — even for cells obtained from ATCC. Caco-2™ cells may not be distributed or used for any commercial uses without the prior written authorization of NaviCyte Scientific. Please see below for more information.

NaviCyte’s Exclusive Commercial Rights to CACO-2™.

The Caco-2™ cell line originated in the laboratories of the Memorial Sloan-Kettering Cancer Center (MSKCC) in 1974. n 1982, MSKCC deposited Caco-2™ with the American Type Culture Collection (ATCC) as the sole distributor of Caco-2™ to the non-profit research community. This deposit was made subject to explicit restrictions to the effect that Caco-2™ cells would not be utilized by any third party for commercial purposes or redistributed by anyone without MSKCC’s prior approval.

ATCC routinely informs its customers that the Caco-2™ cell line distributed by ATCC is restricted to non-commercial research uses by non-profit organizations. This notification includes conspicuous notices in its product catalogs (under ATCC’s “HTB-37” classification for Caco-2™) and in its order form. Unauthorized commercial uses include any uses of Caco-2™ by a for-profit entity, including the use of Caco-2TM in R&D and drug discovery activities of a life sciences company, reselling of Caco-2™ cells, any patent filings based on research utilizing Caco-2™ and any fee-for-research services offering involving Caco-2™.

MSKCC has granted to NaviCyte Scientific the exclusive license and right to distribute the Caco-2™ cell line to third parties for commercial uses. ATCC routinely refers any interested commercial entities to NaviCyte. NaviCyte can provide written confirmation from MSKCC of NaviCyte’s exclusive commercial distribution rights to Caco-2TM upon request.
NaviCyte has entered into a number of non-exclusive internal use licenses granting the right to use Caco-2™ for commercial purposes, including the right to culture the Caco-2™ cells. Commercial agreements include (among others):

  • Abbvie
  • Anadys Pharmaceuticals, Inc.
  • ArQule
  • Astellas
  • AstraZeneca
  • Bristol-Myers Squibb
  • Biogen IDEC
  • Cubist Pharmaceuticals
  • Galapagos
  • Galleon Pharmaceuticals
  • La Jolla Pharmaceuticals
  • Mead Johnson
  • Merck & Co.
  • Microbia
  • Pfizer
  • Sanofi Pasteur
  • Sekisui Medical Company
  • Syngene International
  • UCB Celltech
  • Major U.S.-based biotechnology companies (with market caps of $50+ billion)
  • Major U.S.-based life science companies (with a market caps of $1.5+ billion)
  • Large multinational pharmaceutical companies

 
Any use of Caco-2™ by a for-profit entity may constitute an unauthorized use, unless the proper license and authorization for this use has been obtained directly from NaviCyte.

The Caco-2Up-To-Date Initiative

NaviCyte has commenced the Caco-2Up-To-Date, a coordinated effort to bring companies’ use of Caco-2™ cell lines into compliance without a penalty.

Companies who wish to take advantage of the benefits offered by the Caco-2Up-To-Date program must enter into a license and commercial use agreement with NaviCyte which covers their future uses of the Caco-2™ cell line as well as any unauthorized past uses. License and use fees are payable for annual or perpetual uses and payment terms may be coordinated with the company’s research budget.

If you would like to obtain or use Caco-2™ cells for any commercial purposes whatsoever, please contact NaviCyte Scientific to obtain the proper commercial use license for the Caco-2™ cells. Contact@NaviCyte-Scientific.com or Elizabeth Aden at +1-973-868-6100

If you have used Caco-2™ cells commercially without proper authorization, you may be eligible to participate in the Caco-2 Up-To-Date program. Please contact NaviCyte Scientific immediately.

Caco-2 Cell Line

SYGNIS is licensing the use of the CaCo2 cell line and its subclone C2BBe1 to interested parties. SYGNIS has an exclusive agreement with Memorial Sloan-Kettering Cancer Center (MSKCC), the originator of this cell line, to license this important cell line.

The Caco-2 cell line was derived from a carcinoma of the large intestine. The primary use of these cell lines in pharmaceutical studies for drug development, particularly for absorption of orally bioavailable molecules and transporter studies. For these assays, the cells are grown as a monolayer on support matrices where they partially differentiate to form a polarized cell layer showing many of the transport characteristics of the intestinal mucosa. Hallmarks of this cell layer are the presence of tight junctions, microvilli, expression of P-glycoprotein and various transporters. This monolayer model can be used to measure the permeability of drug candidates, and allows a company to predict the oral bioavailability and absorption kinetics of compounds that correlates reasonably well with in vivo human clinical data. The Caco-2 assay has been extensively characterized and is the recognized gold standard for absorption assays. It is part of many standard pre-clinical (ADME) substance characterization packages used in the pharmaceutical industry.

NaviCyte is a trademark of LION bioscience Inc. (a company of SYGNIS Group). CACO-2 is a trademark of the Memorial Sloan-Kettering Cancer Center.


[/vc_column_text][/vc_tab][vc_tab title="Contact Us" tab_id="1421322440-2-005"][vc_column_text]

Contact Information and Directions

01
01
NaviCyte Scientific, a division of LION bioscience Inc.

Contact Information:
Elizabeth R Aden, PhD
NaviCyte Scientific
3030 Buena Vista Way
Berkeley, CA 94708
Phone: +1 973-868-6100
Fax: +1 510-548-7676

email: contact@navicyte-scientific.com

NaviCyte is a trademark of LION bioscience Inc. (a company of SYGNIS Group). CACO-2 is a trademark of the Memorial Sloan-Kettering Cancer Center.

[/vc_column_text][/vc_tab][/vc_tabs]

  • SYGNIS und Expedeon schließen sich zusammen. Sie werden jetzt auf die Webseite von Expedeon umgeleitet, wo Sie alle SYGNIS-Produkte bestellen können. Des weiteren haben Sie Zugang zu produktbezogenen Informationen und vielen weiteren technischen Ressourcen.

    ok

  • SYGNIS und Expedeon schließen sich zusammen. Sie werden jetzt auf die Webseite von Expedeon umgeleitet, wo Sie alle SYGNIS-Produkte bestellen können. Des weiteren haben Sie Zugang zu produktbezogenen Informationen und vielen weiteren technischen Ressourcen.

    ok

  • SYGNIS und Expedeon schließen sich zusammen. Sie werden jetzt auf die Webseite von Expedeon umgeleitet, wo Sie alle SYGNIS-Produkte bestellen können. Des weiteren haben Sie Zugang zu produktbezogenen Informationen und vielen weiteren technischen Ressourcen.

    ok

  • SYGNIS und Expedeon schließen sich zusammen. Sie werden jetzt auf die Webseite von Expedeon umgeleitet, wo Sie alle SYGNIS-Produkte bestellen können. Des weiteren haben Sie Zugang zu produktbezogenen Informationen und vielen weiteren technischen Ressourcen.

    ok

  • SYGNIS und Expedeon schließen sich zusammen. Sie werden jetzt auf die Webseite von Expedeon umgeleitet, wo Sie alle SYGNIS-Produkte bestellen können. Des weiteren haben Sie Zugang zu produktbezogenen Informationen und vielen weiteren technischen Ressourcen.

    ok

  • SYGNIS und Expedeon schließen sich zusammen. Sie werden jetzt auf die Webseite von Expedeon umgeleitet, wo Sie alle SYGNIS-Produkte bestellen können. Des weiteren haben Sie Zugang zu produktbezogenen Informationen und vielen weiteren technischen Ressourcen.

    ok

  • SYGNIS und Expedeon schließen sich zusammen. Sie werden jetzt auf die Webseite von Expedeon umgeleitet, wo Sie alle SYGNIS-Produkte bestellen können. Des weiteren haben Sie Zugang zu produktbezogenen Informationen und vielen weiteren technischen Ressourcen.

    ok

  • SYGNIS y Expedeon se encuentran en proceso de fusión. A continuación, será transferido al sitio web de Expedeon, donde podrá adquirir productos SYGNIS, consultar manuales de producto y otros recursos técnicos.

    ok

  • SYGNIS y Expedeon se encuentran en proceso de fusión. A continuación, será transferido al sitio web de Expedeon, donde podrá adquirir productos SYGNIS, consultar manuales de producto y otros recursos técnicos.

    ok

  • SYGNIS y Expedeon se encuentran en proceso de fusión. A continuación, será transferido al sitio web de Expedeon, donde podrá adquirir productos SYGNIS, consultar manuales de producto y otros recursos técnicos.

    ok

  • SYGNIS y Expedeon se encuentran en proceso de fusión. A continuación, será transferido al sitio web de Expedeon, donde podrá adquirir productos SYGNIS, consultar manuales de producto y otros recursos técnicos.

    ok

  • SYGNIS y Expedeon se encuentran en proceso de fusión. A continuación, será transferido al sitio web de Expedeon, donde podrá adquirir productos SYGNIS, consultar manuales de producto y otros recursos técnicos.

    ok

  • SYGNIS y Expedeon se encuentran en proceso de fusión. A continuación, será transferido al sitio web de Expedeon, donde podrá adquirir productos SYGNIS, consultar manuales de producto y otros recursos técnicos.

    ok

  • SYGNIS y Expedeon se encuentran en proceso de fusión. A continuación, será transferido al sitio web de Expedeon, donde podrá adquirir productos SYGNIS, consultar manuales de producto y otros recursos técnicos.

    ok

  • SYGNIS and Expedeon are merging. You are now being transferred to Expedeon’s website. where you can order all SYGNIS’ products as well as consult product literature and many other technical resources.

    ok

  • SYGNIS and Expedeon are merging. You are now being transferred to Expedeon’s website. where you can order all SYGNIS’ products as well as consult product literature and many other technical resources.

    ok

  • SYGNIS and Expedeon are merging. You are now being transferred to Expedeon’s website. where you can order all SYGNIS’ products as well as consult product literature and many other technical resources.

    ok

  • SYGNIS and Expedeon are merging. You are now being transferred to Expedeon’s website. where you can order all SYGNIS’ products as well as consult product literature and many other technical resources.

    ok

  • SYGNIS and Expedeon are merging. You are now being transferred to Expedeon’s website. where you can order all SYGNIS’ products as well as consult product literature and many other technical resources.

    ok

  • SYGNIS and Expedeon are merging. You are now being transferred to Expedeon’s website. where you can order all SYGNIS’ products as well as consult product literature and many other technical resources.

    ok

  • SYGNIS and Expedeon are merging. You are now being transferred to Expedeon’s website. where you can order all SYGNIS’ products as well as consult product literature and many other technical resources.

    ok

  • SYGNIS and Expedeon are merging. You are now being transferred to Expedeon’s website. where you can order all SYGNIS’ products as well as consult product literature and many other technical resources.

    ok

  • SYGNIS and Expedeon are merging. You are now being transferred to Expedeon’s website. where you can order all SYGNIS’ products as well as consult product literature and many other technical resources.

    ok

  • SYGNIS and Expedeon are merging. You are now being transferred to Expedeon’s website. where you can order all SYGNIS’ products as well as consult product literature and many other technical resources.

    ok

  • SYGNIS and Expedeon are merging. You are now being transferred to Expedeon’s website. where you can order all SYGNIS’ products as well as consult product literature and many other technical resources.

    ok

  • SYGNIS and Expedeon are merging. You are now being transferred to Expedeon’s website. where you can order all SYGNIS’ products as well as consult product literature and many other technical resources.

    ok

  • SYGNIS y Expedeon se encuentran en proceso de fusión. A continuación, será transferido al sitio web de Expedeon, donde podrá adquirir productos SYGNIS, consultar manuales de producto y otros recursos técnicos.

    ok

  • SYGNIS und Expedeon schließen sich zusammen. Sie werden jetzt auf die Webseite von Expedeon umgeleitet, wo Sie alle SYGNIS-Produkte bestellen können. Des weiteren haben Sie Zugang zu produktbezogenen Informationen und vielen weiteren technischen Ressourcen.

    ok

  • SYGNIS and Expedeon are merging. You are now being transferred to Expedeon’s website. where you can order all SYGNIS’ products as well as consult product literature and many other technical resources.

    ok